Brought to you by 
Raven raises $40mm in third round financing
09 Jan 2003
Executive Summary
Monoclonal antibody (MAb) therapeutics developer Raven Biotechnologies closed a $40mm Series C financing round led by Bear Stearns Health Innoventures. Other participants were new investors Pequot Ventures, GE's Life Science and Technology Finance Group, BioMedical Sciences Investment Fund, and Integra Ventures, plus returning investors US Venture Partners, CMEA Ventures, Hambrecht & Quist Capital Management, and Milepost Ventures.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Raven raises $40mm in third round financing
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice